|
1.
|
Dai C and Gu W: p53 post-translational
modification: deregulated in tumorigenesis. Trends Mol Med.
16:528–536. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Appella E and Anderson CW:
Post-translational modifications and activation of p53 by genotoxic
stresses. Eur J Biochem. 268:2764–2772. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Brooks CL and Gu W: Ubiquitination,
phosphorylation and acetylation: the molecular basis for p53
regulation. Curr Opin Cell Biol. 15:164–171. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Brooks CL and Gu W: The impact of
acetylation and deacetylation on the p53 pathway. Protein Cell.
2:456–462. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Gu W and Roeder RG: Activation of p53
sequence-specific DNA binding by acetylation of the p53 C-terminal
domain. Cell. 90:595–606. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Li M, Luo J, Brooks CL and Gu W:
Acetylation of p53 inhibits its ubiquitination by Mdm2. J Biol
Chem. 277:50607–50611. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Liu L, Scolnick DM, Trievel RC, Zhang HB,
Marmorstein R, Halazonetis TD and Berger SL: p53 sites acetylated
in vitro by PCAF and p300 are acetylated in vivo in response to DNA
damage. Mol Cell Biol. 19:1202–1209. 1999.PubMed/NCBI
|
|
8.
|
Sakaguchi K, Herrera JE, Saito S, Miki T,
Bustin M, Vassilev A, Anderson CW and Appella E: DNA damage
activates p53 through a phosphorylation-acetylation cascade. Genes
Dev. 12:2831–2841. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Wang YH, Tsay YG, Tan BC, Lo WY and Lee
SC: Identification and characterization of a novel p300-mediated
p53 acetylation site, lysine 305. J Biol Chem. 278:25568–25576.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Tang Y, Zhao W, Chen Y, Zhao Y and Gu W:
Acetylation is indispensable for p53 activation. Cell. 133:612–626.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Torgersen KM, Vang T, Abrahamsen H, Yaqub
S and Tasken K: Molecular mechanisms for protein kinase A-mediated
modulation of immune function. Cell Signal. 14:1–9. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Blomhoff HK, Blomhoff R, Stokke T, deLange
DC, Brevik K, Smeland EB, Funderud S and Godal T: cAMP-mediated
growth inhibition of a B-lymphoid precursor cell line Reh is
associated with an early transient delay in G2/M, followed by an
accumulation of cells in G1. J Cell Physiol. 137:583–587. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Blomhoff HK, Smeland EB, Beiske K,
Blomhoff R, Ruud E, Bjoro T, Pfeifer-Ohlsson S, Watt R, Funderud S
and Godal T: Cyclic AMP-mediated suppression of normal and
neoplastic B cell proliferation is associated with regulation of
myc and Ha-ras protooncogenes. J Cell Physiol. 131:426–433. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Naderi S, Gutzkow KB, Christoffersen J,
Smeland EB and Blomhoff HK: cAMP-mediated growth inhibition of
lymphoid cells in G1: rapid down-regulation of cyclin D3 at the
level of translation. Eur J Immunol. 30:1757–1768. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Naderi S, Wang JY, Chen TT, Gutzkow KB and
Blomhoff HK: cAMP-mediated inhibition of DNA replication and S
phase progression: involvement of Rb, p21Cip1, and PCNA. Mol Biol
Cell. 16:1527–1542. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Naderi EH, Findley HW, Ruud E, Blomhoff HK
and Naderi S: Activation of cAMP signaling inhibits DNA
damage-induced apoptosis in BCP-ALL cells through abrogation of p53
accumulation. Blood. 114:608–618. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Naderi EH, Jochemsen AG, Blomhoff HK and
Naderi S: Activation of cAMP signaling interferes with
stress-induced p53 accumulation in ALL-derived cells by promoting
the interaction between p53 and HDM2. Neoplasia. 13:653–663.
2011.PubMed/NCBI
|
|
18.
|
Rosenfeld C, Goutner A, Choquet C, Venuat
AM, Kayibanda B, Pico JL and Greaves MF: Phenotypic
characterisation of a unique non-T, non-B acute lymphoblastic
leukaemia cell line. Nature. 267:841–843. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Bradford MM: A rapid and sensitive method
for the quantitation of microgram quantities of protein utilizing
the principle of protein-dye binding. Anal Biochem. 72:248–254.
1976. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Cai R, Kwon P, Yan-Neale Y, Sambuccetti L,
Fischer D and Cohen D: Mammalian histone deacetylase 1 protein is
post-translationally modified by phosphorylation. Biochem Biophys
Res Commun. 283:445–453. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Du M, Perry RL, Nowacki NB, Gordon JW,
Salma J, Zhao J, Aziz A, Chan J, Siu KW and McDermott JC: Protein
kinase A represses skeletal myogenesis by targeting myocyte
enhancer factor 2D. Mol Cell Biol. 28:2952–2970. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Gerhart-Hines Z, Dominy JE Jr, Blattler
SM, Jedrychowski MP, Banks AS, Lim JH, Chim H, Gygi SP and
Puigserver P: The cAMP/PKA pathway rapidly activates SIRT1 to
promote fatty acid oxidation independently of changes in NAD(+).
Mol Cell. 44:851–863. 2011.PubMed/NCBI
|
|
23.
|
Ha CH, Kim JY, Zhao J, Wang W, Jhun BS,
Wong C and Jin ZG: PKA phosphorylates histone deacetylase 5 and
prevents its nuclear export, leading to the inhibition of gene
transcription and cardiomyocyte hypertrophy. Proc Natl Acad Sci
USA. 107:15467–15472. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Luo J, Nikolaev AY, Imai S, Chen D, Su F,
Shiloh A, Guarente L and Gu W: Negative control of p53 by Sir2alpha
promotes cell survival under stress. Cell. 107:137–148. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Wang X, Taplick J, Geva N and Oren M:
Inhibition of p53 degradation by Mdm2 acetylation. FEBS Lett.
561:195–201. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Li M, Chen D, Shiloh A, Luo J, Nikolaev
AY, Qin J and Gu W: Deubiquitination of p53 by HAUSP is an
important pathway for p53 stabilization. Nature. 416:648–653. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Batty N, Malouf GG and Issa JP: Histone
deacetylase inhibitors as anti-neoplastic agents. Cancer Lett.
280:192–200. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Khan O and La Thangue NB: HDAC inhibitors
in cancer biology: emerging mechanisms and clinical applications.
Immunol Cell Biol. 90:85–94. 2012. View Article : Google Scholar : PubMed/NCBI
|
